Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

America is facing a food system shortage. Livestock veterinarians are the new endangered species. Farmers are losing access to the experts they need to keep our food supply safe.

Moat Index gained 1.53% in November, supported by health care and broader market participation. Merck and Amgen were top Moat ...